Investigating how genetic changes in the STAT3 gene affect immune system function
STAT3 variants as a rheostat of immune tolerance
This study is looking at how certain changes in a gene called STAT3 can affect the immune system and possibly lead to autoimmune diseases like type 1 diabetes, and it’s for anyone interested in understanding these conditions better and finding new ways to help manage them.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11014458 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific genetic mutations in the STAT3 gene can lead to immune system dysfunction, which may result in autoimmune diseases like type 1 diabetes. The project involves three collaborative teams that will analyze immune cell behavior in patients with these mutations, use animal models to study the effects of these mutations, and apply advanced CRISPR technology to explore potential genetic repairs. By unraveling these mechanisms, the research aims to identify new therapeutic strategies to restore immune balance and prevent disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with known STAT3 gene mutations or those diagnosed with autoimmune conditions such as type 1 diabetes.
Not a fit: Patients without genetic mutations in the STAT3 gene or those not affected by autoimmune diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve immune tolerance and reduce the risk of autoimmune diseases.
How similar studies have performed: Previous research has shown promising results in understanding immune dysregulation through genetic studies, indicating that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Anderson, Mark S — University of California, San Francisco
- Study coordinator: Anderson, Mark S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.